Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature

    Question

    Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature

    Direct answer

    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine, highlighting survival gains for VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer patients. The therapeutic asset showed improvements across overall survival, progression-free survival, and treatment duration metrics, supporting advancing clinical development pathways in a high-unmet-need oncology indication.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-reports-positive-phase-2b-virage-pancreatic-cancer-data-in-nat-04b638

    POLICY
    Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine, highlighting survival gains for VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer patients. The therapeutic asset showed improvements across overall survival, progression-free survival, and treatment duration metrics, supporting advancing clinical development pathways in a high-unmet-need oncology indication.
    TOVX
    Impact
    65
    OCT 1
    SIG
    85%
    TOVX
    Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in Nature
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine, highlighting survival gains for VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer patients. The therapeutic asset showed improvements across overall survival, progression-free survival, and treatment duration metrics, supporting advancing clinical development pathways in a high-unmet-need oncology indication.
    → Statistically validated Phase 2b overall survival improvements in Nature Medicine de-risk Phase 3 design and partnership monetization value for TOVX oncolytic adenovirus pipeline.
    Impact
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine, highlighting survival gains for VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer patients. The therapeutic asset showed improvements across overall survival, progression-free survival, and treatment duration metrics, supporting advancing clinical development pathways in a high-unmet-need oncology indication.
    Affected
    TOVX
    Transmission
    Statistically validated Phase 2b overall survival improvements in Nature Medicine de-risk Phase 3 design and partnership monetization value for TOVX oncolytic adenovirus pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXclinical de-risking and pipeline valuation re-ratingUp1-5dNature Medicine publication confirmed improved OS and PFS in Phase 2b pancreatic cancer trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month